Clinical TrialJul 14, 2026, 07:31 AM
CervoMed: Neflamapimod Phase 2b Data Reinforces DLB Efficacy
AI Summary
CervoMed Inc. presented new clinical, plasma biomarker, and imaging data for neflamapimod in Dementia with Lewy Bodies (DLB) at AAIC 2026. New analyses of the Phase 2b RewinD-LB trial reinforced the treatment effect in "pure" DLB patients and those with adequate drug exposure, supporting the selection of a 50 mg TID dose for the planned Phase 3 study. The data also showed neflamapimod slowed basal forebrain atrophy and increased connectivity. Additionally, a new Phase 2 study for an 80 mg BID dose met safety and tolerability objectives with encouraging clinical activity. The company has aligned with regulatory bodies for the Phase 3 trial and is seeking a strategic partner.
Key Highlights
- New analyses of Phase 2b RewinD-LB trial reinforce neflamapimod's treatment effect in "pure" DLB.
- Data supports selection of 50 mg TID dose for planned Phase 3 study in DLB.
- Neflamapimod produced durable slowing of basal forebrain atrophy over 48 weeks.
- New Phase 2 study of 80 mg BID met primary safety, tolerability, and PK objectives.
- Plasma Ctrough threshold of ~4 ng/mL associated with biomarker and clinical improvements.
- 50 mg TID dose expected to achieve Ctrough threshold in approximately 90% of patients.
- Alignment achieved with FDA and other regulatory bodies for planned Phase 3 trial.
- CervoMed is seeking a strategic partner to advance neflamapimod into Phase 3.
Price Impact
More from CRVO